Novel small molecule library development

选择、获取和使用高质量的小分子文库进行筛选是药物发现和化学生物学计划的一个重要方面。随着研究人员对小分子对特定生物靶点、过程和环境的适用性有了更高的认识，筛选文库也在不断发展。围绕任何给定小分子文库的组成的决定都受到许多变量的影响，并且对最佳实践的意见各不相同。任何集合的适合性都依赖于预先过滤，以避免有问题的化合物，评估适当的物理化学性质，建立理想的结构独特性水平，并确定所需的分子复杂性程度。随着学术和工业组织从其筛选组合中寻找能够产生不断改进的结果的收藏品，这些标准正在不断进行评估和修订。实际问题，包括成本，化合物管理，筛选复杂性和分析目标也发挥了重要作用的选择库组成。我们的团队继续开发新的库，包括机制询问板或MIPE和用于单药和组合筛选平台的新型稳定代谢物库。这些库是研究多种疾病模型的重要工具。

The selection, acquisition, and use of high-quality, small-molecule libraries for screening are an essential aspect of drug discovery and chemical biology programs. Screening libraries continue to evolve as researchers gain a greater appreciation of the suitability of small molecules for specific biological targets, processes and environments. The decisions surrounding the make-up of any given small molecule library is informed by a multitude of variables, and opinions vary on best-practices. The fitness of any collection relies upon upfront filtering to avoid problematic compounds, assess appropriate physicochemical properties, install the ideal level of structural uniqueness and determine the desired extent of molecular complexity. These criteria are under constant evaluation and revision as academic and industrial organizations seek out collections that yield ever-improving results from their screening portfolios. Practical questions including cost, compound management, screening sophistication and assay objective also play a significant role in the choice of library composition. Our team continues to develop novel libraries including the Mechanism Interrogation Plate or MIPE and a novel stable metabolite library for use in both single agent and combination screening platforms. These libraries represent important tools for studying multiple models of disease.